Molecular Diagnostics

High-Risk Female Groups Screened for Fabry Disease
Although measurement of lysosomal α-galactosidase A in women is not accurate for the diagnosis of Fabry disease, determining the range of the enzyme activity presented by heterozygous females could become a valuable tool for minimizing the burden of screening by DNA sequencing all potential carriers. More...26 Jun 2014






In Other News
New Software Tool Rapidly Finds Links Between Mutations and Disease in Families
Exome Sequencing Covers Specific Gene Sets Ineffectually
Microarray Analysis of Gene Expression Signatures in Blood Samples Provides Biomarker for Higher Cardiovascular Death Risk
New Multigene Test Improves Assessment of Hereditary Cancers
Many Healthy Adults Infected with Human Papilloma Viruses
Nasal Bacteria Could Predict Skin Infections
Innovative Approach Developed for Sampling Gut Bacteria
Gene Mutation Found for Aggressive Form of Pancreatic Cancer
Partnership with Lilly Expands Qiagen’s Personalized Healthcare Pipeline
Gene Panel May Be Able to Identify Existing and Potential Alcoholics
CAP/CLIA Lab Launches New Robust Prototype Assays
Two Genes Together Drive Aggressive Prostate Cancer
Promising Biomarker Discovered for Esophageal Cancer
Simple Blood Test Could Improve Treatment for Neuroblastoma
Novel Gene Expression Blood Test Predicts Premature Birth
Esophageal Cancer Test Identifies Patients Resistance to Chemoradiation Therapy
DNA Test Launched for Laser Eye Surgery Safety
Studies Confirm Prognostic Value of Multigene Test for Prostate Cancer
Genetic Locus Associated with the Tyrosine Phosphokinase Gene Is an OCD Biomarker
Genetic Risk Factor for Premature Birth Found
Duplicated Gene Found for Highly Prevalent Facial Anomaly
Noninvasive Analysis of Mother's Blood Detects Fetal Chromosomal Abnormalities
Exome Sequencing Will Help Diagnose Patients with Unknown Disorders
Genetic Testing channel of LabMedica brings the latest in molecular genetics, cytogenetics, and epigenetics, and methods from PCR to FISH, and more.